Webinar: From Utah the U.K.—Why Companies Should Consider an IPO on the London Stock Exchange
May 14, 2021
On May 12, 2021, BioUtah presented a webinar featuring representatives of the banking firm, Stifel, as well as James McCullough, CEO of Renalytix, a Utah based company. The webinar presented the opportunity for Utah companies to raise capital through an offering on London Stock Exchange’s AIM platform. Renalytix is one of the most successful companies in years to do just that skipping the traditional process of raising early stage and venture capital.
If you did not have the opportunity to tune in, you can click on the link below to watch the full one hour webinar. It is a unique opportunity for raising capital.
Recent News
- RefloDx Closes $2 Million Seed Round to Advance Noninvasive Testing for Chronic Throat and Voice Symptoms
- Myriad Genetics Releases New MONSTAR-SCREEN-3 Data Demonstrating the Potential of Ultra-Sensitive MRD Detection in Colorectal and Pancreatic Cancers
- Ultragenyx sells second rare pediatric PRV in a week for $203M
- Co-Diagnostics’ Joint Venture CoMira Diagnostics Invited by Saudi Ministry to Participate in Strategic Manufacturing Forum
- Route 92 Medical Announces $100 Million Corporate Debt Facility
- Myriad Genetics and Labcorp Announce Definitive Agreement for Myriad to Sell Prenatal Health Testing Business to Labcorp
